Nova Minerals Limited

NVA

Nova Minerals Ltd. engages in the exploration and development of mineral properties. The company is headquartered in Melbourne, Victoria. The principal activity of the Company is focused on the exploration for and evaluation of mineral deposits. Its projects include Estelle Gold project, RPM, Korbel, Train, and Stoney. The Company’s flagship Estelle Gold Project contains multiple mining resources across a 35 kilometers (km) long mineralized corridor of over 20 identified gold prospects, including two already defined multi-million-ounce resources across four deposits. The RPM project is located in the south of the tenement and comprises: The RPM North Deposit and The RPM South Deposit. The Korbel project is located in the tenement’s north and comprises: The Korbel Main Deposit, The Cathedral Deposit, and six other prospects at varying levels of exploration within the Korbel Valley, all close to the proposed processing plant site. The firm also has a diversified portfolio in other minerals, such as Snow Lake Resources Ltd, and Asra Minerals.

Novo Resources Corp.

NVO

Novo Resources Corp. engages in the evaluation, acquisition, and exploration of natural resource properties with a focus on gold. The company is headquartered in Vancouver, British Columbia and currently employs 37 full-time employees. The company went IPO on 2010-06-14. The firm is engaged primarily in the business of evaluating, acquiring, exploring, and developing natural resource properties with a focus on gold. The company has a land package covering approximately 6,700 square kilometers in the Pilbara region of Western Australia, along with the 22 square kilometer Belltopper project in the Bendigo Tectonic Zone of Victoria, Australia. Its key project area is the Egina Gold Camp, where De Grey Mining is farming-in to form a JV at the Becher Project and surrounding tenements through exploration. The firm is also advancing gold exploration at Nunyerry North. The company focuses on undertaking early-stage exploration across its Pilbara tenement portfolio. The company has also formed lithium joint ventures with both Liatam and SQM in the Pilbara which provides shareholder exposure to battery metals. Its Belltopper Gold Project comprises the adjacent Malmsbury and Queens projects.

Nuheara Limited

NUH

Nuheara Ltd. engages in the development and commercialization of proprietary hearing and wearable technology platforms. The company is headquartered in Perth, Western Australia. The company went IPO on 2010-03-05. The principal activity of the Company is the development and commercialization of its hearing technology and products as regulated medical devices. The firm is focused on developing multi-functional, personalized, intelligent hearing devices that augment a person’s hearing. Its products include IQbuds2 MAX, IQstream TV, Bluetooth Transmitter and others. The company also offers IQbuds2 replacement parts, which include IQbuds2 MAX (Left or Right), IQbuds2 MAX Charging Case and IQbuds2 MAX Soundport Mesh. The firm has Ear ID technology, which provides research-grade tailored hearing. Its products are sold direct to consumer (DTC) and in consumer electronics retailers, professional hearing clinics, pharmacies and specialty retailers around the world. Its subsidiaries include Nuheara IP Pty Ltd, Nuheara, Inc, Terrace Gold Pty Ltd, Nuheara (UK) Ltd, Nuheara (Canada) Inc and Nuheara NL B.V.

Neurizon Therapeutics Limited

NUZ

Neurizon Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-10-05. Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The firm is engaged in advancing treatments for neurodegenerative diseases. The firm is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.